Bausch + Lomb's Saunders doesn't expect more big deals in the near term

Eye care firm Bausch + Lomb (BLCO.TO) does not expect to do another big deal for around a year after it completes its $1.75 billion deal for dry eye drug Xiidra, recently rehired chief executive Brent Saunders said on Wednesday.